Zymeworks Inc. — Form 8-K
Filed August 25, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Jazz Pharmaceuticals received FDA approval for Ziihera (zanidatamab) in first-line HER2+ gastroesophageal adenocarcinoma, both with and without tislelizumab plus chemotherapy. Zymeworks receives a $250M milestone payment from Jazz (total upfront+milestones: $650M) and remains eligible for up to $1.3B additional milestones plus 10–20% tiered royalties. This is zanidatamab's second FDA approval in less than two years; separately, BeOne collaboration has yielded $81M to date with up to $144M additional milestones plus up to 19.5% royalties.
Why this rating
Second major approval validates platform; $250M immediate cash (~39% of market cap) plus $1.3B upside materially strengthens cash flow runway and royalty diversification for this $649.5M company.
Tradability signal
NO TRADE
No trade: positive news with only +0.4% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.13% over 4 hrs, n=14).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $28.13 ▼ 0.42% | at our read · backfill $28.25 | +10 min · backfill $27.53 ▼ 2.53% | +30 min · backfill $28.22 ▼ 0.10% | +1 hr · backfill $26.78 ▼ 5.20% | +4 hrs · backfill $27.05 ▼ 4.25% |
The stock had already moved +0.43% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.